Use of COVID-19 Vaccines in the United States
Interim Clinical Considerations
Interim Clinical Considerations
Summary of recent changes (last updated October 31, 2024):
- People ages 65 years and older, vaccinated under the routine schedule, are recommended to receive 2 doses of any 2024–2025 COVID-19 vaccine (i.e., Moderna, Novavax, or Pfizer-BioNTech) separated by 6 months (minimum interval 2 months) regardless of vaccination history, with one exception: Unvaccinated people who initiate vaccination with 2024–2025 Novavax COVID-19 Vaccine are recommended to receive 2 doses of Novavax followed by a third dose of any COVID-19 vaccine 6 months (minimum interval 2 months) later.
- People ages 6 months and older who are moderately or severely immunocompromised are recommended to receive:
- Unvaccinated: A multidose initial series with an age-appropriate COVID-19 vaccine and 1 dose 6 months (minimum interval 2 months) after completion of the initial series; may receive additional doses under shared clinical decision making
- Previously completed the multidose initial series: 2 age-appropriate doses of 2024–2025 COVID-19 vaccine 6 months (minimum interval 2 months) apart; may receive additional doses under shared clinical decision making
Reference Materials
- COVID-19 Vaccine Product Information (Updated 9/27/24)
Get Email Updates
Receive email updates about this page.
Special Situations and Populations
References and Previous Updates